Soria Ester Banque - 05 Jul 2026 Form 4 Insider Report for Moderna, Inc. (MRNA)

Reporting relationship: Chief Commercial Officer
Issuer ticker: MRNA
Reported as of: 05 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Jul 2026, 16:25:50 UTC
Prior SEC filing: 30 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ James Dillon, as Attorney-in-Fact

Key filing fact

Soria Ester Banque filed Form 4 for Moderna, Inc. (MRNA) on 07 Jul 2026.

Key facts

This page summarizes Soria Ester Banque's Form 4 filing for Moderna, Inc. (MRNA).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 07 Jul 2026, 16:25.

Change

Previous filing in this sequence was filed on 30 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001985166 Primary reporting owner

Banque Soria Ester

Relationship: Chief Commercial Officer
Address: C/O MODERNA, INC., 325 BINNEY STREET, CAMBRIDGE
Signature: /s/ James Dillon, as Attorney-in-Fact
Signature date: 07 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MRNA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +18,658
Change %
Price: $0.000000^*
Shares after: 18,658
Date: 05 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 18,658
Exercise price: $79.76
Footnotes: F1

MRNA transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +38,364
Change %
Price: $0.000000^*
Shares after: 38,364
Date: 05 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 38,364
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

25% of this option will vest and become exercisable on July 5, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

Footnote F2

Restricted stock units convert into common stock on a one-for-one basis.

Footnote F3

25% of the shares subject to this restricted stock unit award will vest on July 5, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter.